Expert Panel to Discuss Innovations in Alzheimer's Disease Clinical Trials

In this free expert panel discussion, hear from thought-leaders from across industry and academia on the transformative power of at-home and in-clinic innovations in central nervous system (CNS) clinical trials. Attendees will learn how digital biomarkers have the potential to transform CNS clinical trials much the same way that next-generation sequencing has transformed oncology, enabling personalized treatment. The featured panelists will discuss the power of longitudinal EEG data synchronized with behavioral assessment data, and how this can enable leaner trial designs and accelerate clinical development of CNS therapies.

TORONTO, Aug. 29, 2025 /PRNewswire/ -- As Alzheimer's clinical trials continue to evolve, the panel will discuss the latest advances in real-world longitudinal data collection, featuring key findings from a first-in-class study (CNS-101) presented at the recent Alzheimer's Association International Conference (AAIC) by Cumulus Neuroscience.

Expert panelists:

Dr. Ruth McKernan, FMEdSci CBE, Operating Partner, SV Health Investors, CEO, Draig Therapeutics and Chair, Cumulus Neuroscience
Professor James Rowe, BA BMBCh FRCP PhD, Director of Cambridge Centre for Frontotemporal Dementia and Related Disorders, Department of Clinical Neurosciences, University of Cambridge and Chief Investigator for CNS-101
Bryan J. Hansen, PhD, Pharma Neuroscientist, Technologist, and Innovator
Brian Murphy, PhD, Co-Founder and CSO, Cumulus Neuroscience